Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Cash & Current Investments (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Cash & Current Investments for 11 consecutive years, with $4.5 billion as the latest value for Q4 2025.

  • Quarterly Cash & Current Investments rose 73.08% to $4.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.5 billion through Dec 2025, up 73.08% year-over-year, with the annual reading at $4.5 billion for FY2025, 73.08% up from the prior year.
  • Cash & Current Investments for Q4 2025 was $4.5 billion at BeOne Medicines, up from $4.0 billion in the prior quarter.
  • The five-year high for Cash & Current Investments was $5.7 billion in Q2 2022, with the low at $1.9 billion in Q1 2022.
  • Average Cash & Current Investments over 5 years is $3.5 billion, with a median of $3.2 billion recorded in 2023.
  • The sharpest move saw Cash & Current Investments skyrocketed 239.52% in 2021, then crashed 60.56% in 2022.
  • Over 5 years, Cash & Current Investments stood at $2.2 billion in 2021, then soared by 102.24% to $4.5 billion in 2022, then fell by 30.0% to $3.2 billion in 2023, then dropped by 17.23% to $2.6 billion in 2024, then soared by 73.08% to $4.5 billion in 2025.
  • According to Business Quant data, Cash & Current Investments over the past three periods came in at $4.5 billion, $4.0 billion, and $2.8 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.